微小RNA-375在肿瘤中的表达及作用

国际肿瘤学杂志››2016,Vol. 43››Issue (6): 442-444.doi:10.3760/cma.j.issn.1673-422X.2016.06.011

微小RNA-375在肿瘤中的表达及作用

刘阳，陈楠，庞金桥，熊成秀，李高峰

650118 昆明医科大学第三附属医院云南省肿瘤医院胸外科

收稿日期:2016-01-14出版日期:2016-06-08发布日期:2016-04-27
通讯作者:李高峰 E-mail:ligaofenghl@126.com
基金资助:

国家自然科学基金（81460356）

Expression and role of microRNA-375 in cancer

Liu Yang, Chen Nan, Pang Jinqiao, Xiong Chengxiu, Li Gaofeng

Department of Thoracic Surgery, Third Affiliated Hospital of Kunming Medical University ﹠ Tumor Hospital of Yunnan Province, Kunming 650118, China

Received:2016-01-14Online:2016-06-08Published:2016-04-27
Contact:Li Gaofeng E-mail:ligaofenghl@126.com
Supported by:

National Natural Science Foundation of China (81460356)

摘要/Abstract

摘要：微小RNA-375（miR-375）与多种肿瘤的发生发展密切相关，如肝癌、胃癌、胰腺癌、子宫内膜癌、食管癌、非小细胞肺癌等。miR-375相关的肿瘤发病机制主要包括其与特定靶基因结合，并在转录后水平降解mRNA或抑制蛋白翻译，发挥抑制细胞增殖、促进细胞凋亡、抑制侵袭转移等抑癌作用。miR-375有望成为肿瘤治疗的一个新靶点，并可能成为肿瘤诊断、治疗及预后判断的一个重要生物标志物。

关键词:微RNAs,肿瘤

Abstract:MicroRNA-375 (miR-375) is closely related to the development of cancer, such as liver cancer, gastric cancer, pancreatic cancer, endometrial cancer, esophageal cancer, non-small cell lung cancer, etc. The mainly tumor pathogenesis related miR375 includes that miR375 is combined with specific target genes, can degrade mRNA or inhibit protein translation in the transcriptional level, and plays antitumor effect of inhibition of cell proliferation, promoting cell apoptosis and inhibiting the invasion and metastasis. miR375 is expected to be a new target for cancer therapy, which may become an important biomarker for the diagnosis, treatment and prognosis of cancer.

Key words:MicroRNAs,Neoplasms

刘阳，陈楠，庞金桥，熊成秀，李高峰. 微小RNA-375在肿瘤中的表达及作用[J]. 国际肿瘤学杂志, 2016, 43(6): 442-444.

Liu Yang, Chen Nan, Pang Jinqiao, Xiong Chengxiu, Li Gaofeng. Expression and role of microRNA-375 in cancer[J]. Journal of International Oncology, 2016, 43(6): 442-444.

参考文献

［1］ Shao Y, Geng Y, Gu W, et al. Prognostic significance of microRNA375 downregulation in solid tumors: a metaanalysis［J］. Dis Markers, 2014, 2014: 626185. DOI: 10.1155/2014/626185. ［2］ Pasquinelli AE. MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship［J］. Nat Rev Genet, 2012, 13(4): 271-282. DOI: 10.1038/nrg3162. ［3］ Shrestha S, Hsu SD, Huang WY, et al. A systematic review of microRNA expression profiling studies in human gastric cancer［J］. Cancer Med, 2014, 3(4): 878-888. DOI: 10.1002/cam4.246. ［4］ Wang L, Song G, Liu M, et al. MicroRNA375 overexpression influences P19 cell proliferation, apoptosis and differentiation through the Notch signaling pathway［J］. Int J Mol Med, 2016, 37(1): 47-55. DOI: 10.3892/ijmm.2015.2399. ［5］ Ding L, Xu Y, Zhang W, et al. MiR375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2［J］. Cell Res, 2010, 20(7): 784-793. DOI: 10.1038/cr.2010.79. ［6］ Tsukamoto Y, Nakada C, Noguchi T, et al. MicroRNA375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 1433zeta［J］. Cancer Res, 2010, 70(6): 2339-2349. DOI: 10.1158/00085472.CAN-09-2777. ［7］ Xu Y, Jin J, Liu Y, et al. Snailregulated miR375 inhibits migration and invasion of gastric cancer cells by targeting JAK2［J］. PLoS One, 2014, 9(7): e99516. DOI: 10.1371/journal.pone. 0099516. ［8］ Miao L, Liu K, Xie M, et al. MiR375 inhibits Helicobacter pyloriinduced gastric carcinogenesis by blocking JAK2STAT3 signaling［J］. Cancer Immunol Immunother, 2014, 63(7): 699-711. DOI: 10.1007/s00262-014-1550-y. ［9］ He XX, Chang Y, Meng FY, et al. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo［J］. Oncogene, 2012, 31(28): 3357-3369. DOI: 10.1038/onc.2011.500. ［10］ Yang T, Zhao P, Rong Z, et al. Antitumor efficiency of lipidcoated cisplatin nanoparticles coloaded with microRNA375［J］. Theranostics, 2016, 6(1): 142-154. DOI: 10.7150/thno.13130. ［11］ Jung HI, Ahn T, Bae SH, et al. Astrocyte elevated gene1 overexpression in hepatocellular carcinoma: an independent prognostic factor［J］. Ann Surg Treat Res, 2015, 88(2): 7785. DOI: 10.4174/astr.2015.88.2.77. ［12］ Song S, Zhou J, He S, et al. Expression levels of microRNA375 in pancreatic cancer［J］. Biomed Rep, 2013, 1(3): 393-398. ［13］ Li W, Lebrun DG, Li M, et al. The expression and functions of microRNAs in pancreatic adenocarcinoma and hepatocellular carcinoma［J］. Chin J Cancer, 2011, 30(8): 540-550. DOI: 10.5732/cjc.011.10197. ［14］ Zhou J, Song S, He S, et al. MicroRNA375 targets PDK1 in pancreatic carcinoma and suppresses cell growth through the Akt signaling pathway［J］. Int J Mol Med, 2014, 33(4): 950956. DOI: 10.3892/ijmm.2014.1638. ［15］ Xu L, Li M, Wang M, et al. The expression of microRNA375 in plasma and tissue is matched in human colorectal cancer［J］. BMC Cancer, 2014, 14(1): 714. DOI: 10.1186/1471-2407-14-714. ［16］ Wang Y, Tang Q, Li M, et al. MicroRNA375 inhibits colorectal cancer growth by targeting PIK3CA［J］. Biochem Biophys Res Commun, 2014, 444(2): 199204. DOI: 10.1016/j.bbrc.2014.01.028. ［17］ Kong KL, Kwong DL, Chan TH, et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulinlike growth factor 1 receptor［J］. Gut, 2012, 61(1): 33-42. DOI: 10.1136/gutjnl-2011-300178. ［18］ Li X, Lin R, Li J. Epigenetic silencing of microRNA375 regulates PDK1 expression in esophageal cancer［J］. Dig Dis Sci, 2011, 56(10): 2849-2856. DOI: 10.1007/s10620-011-1711-1. ［19］ Isozaki Y, Hoshino I, Akutsu Y, et al. Usefulness of microRNA375 as a prognostic and therapeutic tool in esophageal squamous cell carcinoma［J］. Int J Oncol, 2015, 46(3): 1059-1066. DOI: 10.3892/ijo.2014.2789. ［20］ Shen Y, Wang P, Li Y, et al. miR375 is upregulated in acquired paclitaxel resistance in cervical cancer［J］. Br J Cancer, 2013, 109(1): 92-99. DOI: 10.1038/bjc.2013.308. ［21］ Shen Y, Zhou J, Li Y, et al. MiR375 mediated acquired chemoresistance in cervical cancer by facilitating EMT［J］. PLoS One, 2014, 9(10): e109299. DOI: 10.1371/journal.pone.0109299. ［22］叶文蔚, 李甫钥, 叶夏斌, 等. MiR375在子宫内膜癌HEC1B细胞中的生物学功能［J］. 实用医学杂志, 2013, 29(2): 177-180. ［23］ Jin Y, Liu YL, Zhang J, et al. The expression of miR375 is associated with carcinogenesis in three subtypes of lung cancer［J］. PLoS One, 2015, 10(12): e0144187. DOI: 10.1371/journal.pone.0144187.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.